These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 26580349)

  • 1. Clinical-pharmacist intervention reduces clinically relevant drug-drug interactions in patients with heart failure: A randomized, double-blind, controlled trial.
    Roblek T; Deticek A; Leskovar B; Suskovic S; Horvat M; Belic A; Mrhar A; Lainscak M
    Int J Cardiol; 2016 Jan; 203():647-52. PubMed ID: 26580349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prevalence of potential drug-drug interactions in patients with heart failure at hospital discharge.
    Straubhaar B; Krähenbühl S; Schlienger RG
    Drug Saf; 2006; 29(1):79-90. PubMed ID: 16454536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized clinical trial of a postdischarge pharmaceutical care program vs regular follow-up in patients with heart failure.
    López Cabezas C; Falces Salvador C; Cubí Quadrada D; Arnau Bartés A; Ylla Boré M; Muro Perea N; Homs Peipoch E
    Farm Hosp; 2006; 30(6):328-42. PubMed ID: 17298190
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection and prevention of drug-drug interactions in the hospitalized elderly: utility of new cytochrome p450-based software.
    Zakrzewski-Jakubiak H; Doan J; Lamoureux P; Singh D; Turgeon J; Tannenbaum C
    Am J Geriatr Pharmacother; 2011 Dec; 9(6):461-70. PubMed ID: 22019006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacist-led intervention in the multidisciplinary team approach optimizes heart failure medication.
    Suzuki M; Matsue Y; Izumi S; Kimura A; Hashimoto T; Otomo K; Saito H; Suzuki M; Kato Y; Funakoshi R
    Heart Vessels; 2018 Jun; 33(6):615-622. PubMed ID: 29204682
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug-drug interaction checking assisted by clinical decision support: a return on investment analysis.
    Helmons PJ; Suijkerbuijk BO; Nannan Panday PV; Kosterink JG
    J Am Med Inform Assoc; 2015 Jul; 22(4):764-72. PubMed ID: 25670751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Postdischarge community pharmacist-provided home services for patients after hospitalization for heart failure.
    Kalista T; Lemay V; Cohen L
    J Am Pharm Assoc (2003); 2015; 55(4):438-42. PubMed ID: 26161487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retrospective drug utilization review: incidence of clinically relevant potential drug-drug interactions in a large ambulatory population.
    Peng CC; Glassman PA; Marks IR; Fowler C; Castiglione B; Good CB
    J Manag Care Pharm; 2003; 9(6):513-22. PubMed ID: 14664659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Revisiting Project Re-Engineered Discharge (RED): The Impact of a Pharmacist Telephone Intervention on Hospital Readmission Rates.
    Sanchez GM; Douglass MA; Mancuso MA
    Pharmacotherapy; 2015 Sep; 35(9):805-12. PubMed ID: 26406772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of pharmacists' intervention on identification and management of drug-drug interactions in an intensive care setting.
    Hasan SS; Lim KN; Anwar M; Sathvik BS; Ahmadi K; Yuan AW; Kamarunnesa MA
    Singapore Med J; 2012 Aug; 53(8):526-31. PubMed ID: 22941130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of the clinical pharmacist in reducing mortality in hospitalized cardiac patients: A prospective, nonrandomized controlled trial using propensity score methods.
    Zhai XB; Tian DD; Liu XY
    Int J Clin Pharmacol Ther; 2015 Mar; 53(3):220-9. PubMed ID: 25546163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Drug-drug interactions in multicentre polypathological polymedicated patients].
    Galindo-Ocaña J; Gil-Navarro MV; García-Morillo JS; Bernabeu-Wittel M; Ollero-Baturone M; Ortiz-Camuñez MA
    Rev Clin Esp; 2010 Jun; 210(6):270-8. PubMed ID: 20434722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An evidence-based assessment of the clinical significance of drug-drug interactions between disease-modifying antirheumatic drugs and non-antirheumatic drugs according to rheumatologists and pharmacists.
    van Roon EN; van den Bemt PM; Jansen TL; Houtman NM; van de Laar MA; Brouwers JR
    Clin Ther; 2009 Aug; 31(8):1737-46. PubMed ID: 19808132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO: a randomized double-blind trial.
    Mortensen SA; Rosenfeldt F; Kumar A; Dolliner P; Filipiak KJ; Pella D; Alehagen U; Steurer G; Littarru GP;
    JACC Heart Fail; 2014 Dec; 2(6):641-9. PubMed ID: 25282031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessing the potential of e-mail for communicating drug therapy recommendations to physicians in patients with heart failure and ventricular-assist devices.
    Lekura J; Tita C; Lanfear DE; Williams CT; Jennings DL
    J Pharm Pract; 2014 Oct; 27(5):478-80. PubMed ID: 24319078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of a wireless handheld medication management device in the prevention of drug-drug interactions in a Medicaid population.
    Malone DC; Saverno KR
    J Manag Care Pharm; 2012; 18(1):33-45. PubMed ID: 22235953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First hospitalization for heart failure in France in 2009: patient characteristics and 30-day follow-up.
    Tuppin P; Cuerq A; de Peretti C; Fagot-Campagna A; Danchin N; Juillière Y; Alla F; Allemand H; Bauters C; Drici MD; Hagège A; Jondeau G; Jourdain P; Leizorovicz A; Paccaud F
    Arch Cardiovasc Dis; 2013 Nov; 106(11):570-85. PubMed ID: 24140417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Negative clinical outcomes associated with drug-related problems in heart failure (HF) outpatients: impact of a pharmacist in a multidisciplinary HF clinic.
    Gastelurrutia P; Benrimoj SI; Espejo J; Tuneu L; Mangues MA; Bayes-Genis A
    J Card Fail; 2011 Mar; 17(3):217-23. PubMed ID: 21362530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effects of three different disease management programs on outcomes in patients hospitalized with heart failure: a randomized trial].
    Gámez-López AL; Bonilla-Palomas JL; Anguita-Sánchez M; Castillo-Domínguez JC; Arizón del Prado JM; Suárez de Lezo J
    Med Clin (Barc); 2012 Mar; 138(5):192-8. PubMed ID: 21605879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized, controlled evaluation of short- and long-term benefits of heart failure disease management within a diverse provider network: the SPAN-CHF trial.
    Kimmelstiel C; Levine D; Perry K; Patel AR; Sadaniantz A; Gorham N; Cunnie M; Duggan L; Cotter L; Shea-Albright P; Poppas A; LaBresh K; Forman D; Brill D; Rand W; Gregory D; Udelson JE; Lorell B; Konstam V; Furlong K; Konstam MA
    Circulation; 2004 Sep; 110(11):1450-5. PubMed ID: 15313938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.